Celltrion Q3 operating profit tops W500 bil. mark for 1st time

Biotech firm Celltrion announced on Monday that its operating profit for the third quarter of 2026 is projected to exceed the 500 billion won mark for the first time, propelled by strong sales in overseas markets. The company's earnings guidance, disclosed on Monday, anticipated 1.5 trillion won in revenue and 510 billion won in operating profit for the three-month period, indicating year-over-year growth of 45.8% and 69.2%, respectively.

Notably, both sales and operating profit reached new quarterly highs, with operating profit surpassing the 500 billion won threshold for the first time since Celltrion's inception. The company attributed its improved profitability to a higher proportion of high-margin products in its sales portfolio and enhancements in its cost structure.

Earlier this year, Celltrion had set quarterly operating profit targets of over 300 billion won for Q1, 400 billion won for Q2, and 500 billion won for Q3. The firm reported that it had surpassed these targets in each of the first three quarters, illustrating that its profit growth trajectory has been on track.